{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:14Z","timestamp":1787008514700,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ACELYRIN Inc."},{"name":"Sharon L. Cross"},{"name":"Affibody and ACELYRIN"},{"name":"Good Publication Practice"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the dose response, efficacy and safety of izokibep in patients with plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this double-blind, randomized, phase II dose-finding study (AFFIRM-35) in adults with moderate-to-severe plaque psoriasis and inadequate response to two or more standard therapies, patients were randomized (1:1:1:1:1) to placebo or izokibep 2, 20, 80 or 160\u2005mg every 2 weeks for 12 weeks. During the remainder of the 52-week core study, patients given placebo were switched to izokibep 80\u2005mg, and dosing intervals were adapted based on Psoriasis Area and Severity Index (PASI) scores for all patients. The core study was followed by two optional consecutive 1-year extension periods for a total duration of 3\u2005years. The primary endpoint was a 90% reduction in PASI score (PASI 90) at week 12. Additional efficacy outcomes and adverse event (AE) rates were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 109 patients were randomized [safety set, n = 108 (one exclusion criteria failure); full analysis set, n = 106]. At week 12, PASI 90 response rates were 0%, 5%, 19%, 71% and 59% for the placebo, 2-, 20-, 80- and 160-mg izokibep groups, respectively. Rapid dose-dependent improvements were also observed across other efficacy outcomes. During the placebo-controlled period, AEs in the izokibep groups were similar to placebo except for mild injection site reactions. AEs were generally mild to moderate and the drug was well tolerated. Izokibep maintained efficacy at the higher dosage groups for up to 3\u2005years, with no new safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Data from this phase II study indicate that izokibep is well tolerated and efficacious in the treatment of plaque psoriasis. Higher doses or more frequent dosing could be explored to further enhance response rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljad186","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:21:31Z","timestamp":1686194491000},"page":"381-391","source":"Crossref","is-referenced-by-count":32,"title":["Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment"],"prefix":"10.1093","volume":"189","author":[{"given":"Sascha","family":"Gerdes","sequence":"first","affiliation":[{"name":"Psoriasis Center, Department of Dermatology, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Center, Medical University Center , Mainz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[{"name":"Germany Private Practice for Dermatology , Wuppertal , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Wetzel","sequence":"additional","affiliation":[{"name":"toclinco GmbH , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weirich","sequence":"additional","affiliation":[{"name":"Rosenpark Research , Darmstadt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes\u00a0","family":"Niesmann","sequence":"additional","affiliation":[{"name":"Private Practice for Dermatology , Bochum , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"da Mota","sequence":"additional","affiliation":[{"name":"Private Practice Dr. Hilton & Partner for Dermatology , D\u00fcsseldorf , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rothhaar","sequence":"additional","affiliation":[{"name":"Rothhaar Studien GmbH , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ardabili","sequence":"additional","affiliation":[{"name":"Derma-Centro-Bochum , Bochum , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Vlasitz","sequence":"additional","affiliation":[{"name":"Affibody AB , Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Feldwisch","sequence":"additional","affiliation":[{"name":"Affibody AB , Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Osterling Koskinen","sequence":"additional","affiliation":[{"name":"Affibody AB , Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Ohlman","sequence":"additional","affiliation":[{"name":"Affibody AB , Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Peloso","sequence":"additional","affiliation":[{"name":"ACELYRIN Inc. , Agoura Hills, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai C","family":"Brun","sequence":"additional","affiliation":[{"name":"Affibody AB , Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik Y","family":"Frejd","sequence":"additional","affiliation":[{"name":"Affibody AB , Solna , Sweden"},{"name":"Department of Immunology , Genetics and Pathology, Uppsala University, Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"2023122117352807500_ljad186-B1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028522","article-title":"Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications","volume":"10","author":"Monin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023122117352807500_ljad186-B2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023122117352807500_ljad186-B3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"2023122117352807500_ljad186-B4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17 A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"2023122117352807500_ljad186-B5","author":"Frejd"},{"key":"2023122117352807500_ljad186-B6","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"MAbs"},{"key":"2023122117352807500_ljad186-B7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"St\u00e5hl","year":"2017","journal-title":"Trends Biotechnol"},{"key":"2023122117352807500_ljad186-B8","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","article-title":"Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis","volume":"170","author":"Wunder","year":"2003","journal-title":"J Immunol"},{"key":"2023122117352807500_ljad186-B9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2023122117352807500_ljad186-B10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"2023122117352807500_ljad186-B11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023122117352807500_ljad186-B12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023122117352807500_ljad186-B13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000156599","article-title":"Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project","volume":"217","author":"Naldi","year":"2008","journal-title":"Dermatology"},{"key":"2023122117352807500_ljad186-B14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study","volume":"41","author":"Piro","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2023122117352807500_ljad186-B15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/bjd.20387","article-title":"Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study","volume":"185","author":"Maul","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023122117352807500_ljad186-B16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2023122117352807500_ljad186-B17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"2023122117352807500_ljad186-B18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023122117352807500_ljad186-B19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomized withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"2023122117352807500_ljad186-B20","doi-asserted-by":"crossref","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2023122117352807500_ljad186-B21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/art.41923","article-title":"Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis\/ankylosing spondylitis initiating interleukin-17 inhibitors: a nationwide population-based study using the French National Health Data System","volume":"74","author":"Penso","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023122117352807500_ljad186-B22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2022-eular.536","article-title":"Izokibep (ABY-035) in patients with active psoriatic arthritis \u201316 week results from a phase 2 study (abstract OP0258)","volume":"81","author":"Behrens","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad186\/51517076\/ljad186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/4\/381\/54726728\/ljad186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/4\/381\/54726728\/ljad186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:17:08Z","timestamp":1703168228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/4\/381\/7230203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,9,12]]},"published-print":{"date-parts":[[2023,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad186","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,12]]}}}